Inhibrx Biosciences, Inc.’s Post

View organization page for Inhibrx Biosciences, Inc., graphic

5,475 followers

On World Lung Cancer Day, we stand with everyone affected by lung cancer, emphasizing the importance of research, early detection, and availability of novel treatments for better patient outcomes. We are investigating our hexavalent OX40 agonist, #INBRX106, in Non-Small Cell Lung Cancer (NSCLC) in our actively enrolling Phase 1 study. Inhibrx is committed to advancing research in lung cancer in the hopes of identifying potential new treatment options. Learn more about our actively enrolling clinical trial here: https://bit.ly/49ZyYks #Inhibrx #BioTechnology

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics